Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

This study will be a single-center, randomized (the treatment is assigned by chance),
double-blind (neither investigator nor volunteer knows the identity of the assigned
treatment), placebo-controlled (one of the study medications is inactive), ascending multiple
dose study (increasing doses of study medication) to assess the pharmacokinetics and
pharmacodynamics of canagliflozin (a drug currently being investigated for the treatment of
type 2 diabetes mellitus) in otherwise healthy obese volunteers. The study will consist of 3
phases: a screening phase, a double-blind treatment phase, and an end of study (or follow-up)
phase. Volunteers will be assigned to 5 cohorts (groups) made up of 16 otherwise healthy
obese men and women. Within each group, 12 volunteers will be given canagliflozin once or
twice daily and 4 volunteers will be given placebo (inactive medication) once or twice daily
for 14 days. The dose of canagliflozin will be different for each of the 5 groups and the
second group will not begin treatment until at least 21 days after the first group start
treatment. This 21-day gap will be applied to all subsequent groups. Each volunteer will
participate in the study for approximately 58 days.

Inclusion Criteria:

- Volunteers must have a body mass index (BMI = weight in kg/height in m2) of 30.0 to
39.9 kg/m2

- Volunteers must be non-diabetic as confirmed by fasting plasma glucose <126 mg/dL

- Volunteers must be non-smoker or non-tobacco users (not smoked cigarettes or used
tobacco-containing products for 3 months prior to screening)

Exclusion Criteria:

- History of or currently active illness considered to be clinically significant by the
Investigator or any other illness that the Investigator considers should exclude the
patient from the study or that could interfere with the interpretation of the study
results

- History of having taken anti-obesity medications (prescription or non-prescription)
within 3 months of the screening visit, or anticipates a need to take any of these
drugs during the course of the study

- History of gastric banding, gastric bypass or other gastric-reduction surgery

- History of eating disorder or recent significant changes in body weight due to dieting
or nutritional treatment